Why the Longevity World Keeps Coming Back to a 70-Year-Old Diabetes Drug

Metformin is not a new discovery. It is not a cutting-edge molecule or a recent addition to the longevity conversation. It has been prescribed continuously since the 1950s, costs pennies a pill, and was originally developed as a diabetes medication. Most people in the longevity space already know the name.

And yet researchers keep coming back to it. The TAME trial, the most ambitious aging study ever approved by the FDA, chose metformin as its test molecule. Longevity physicians who have access to every novel compound on the market keep including it in their protocols. The data keeps expanding into areas nobody predicted.

It does not have a flashy origin story. It does not come in a sleek subscription box. It is generic, it is unglamorous, and the evidence behind it keeps getting more interesting every year. There is a reason for that.

First: What Is It, and Why Should You Trust It?

Let's start with something that gets buried in the fine print but deserves to be the headline.

Metformin is one of the most studied drugs in the history of medicine. Not studied-for-a-few-years-before-approval studied. Not studied-in-a-few-thousand-people studied. It has been in continuous clinical use since the 1950s, prescribed for over 70 years, with a long and well-characterized safety record.

In 2023 alone it was the second most commonly prescribed medication in the United States, with more than 85 million prescriptions. It is on the World Health Organization's List of Essential Medicines, a designation reserved for drugs selected specifically for proven efficacy, safety, and cost-effectiveness.

To put that in perspective: most of the supplements quietly stacked on wellness shelves right now have been tested in a handful of small trials, if that. Many of the longevity molecules generating genuine excitement, rapamycin included, have a few years of human data at best. Metformin has generations of data. Its safety profile is not a question mark. It is one of the most thoroughly documented in all of pharmacology.

Now. What does it actually do?

Metformin is a biguanide, originally derived from the French lilac plant. It works primarily by activating an enzyme called AMPK, often called the body's master metabolic regulator. AMPK activation mimics the cellular effects of caloric restriction and exercise at a molecular level. It reduces glucose production in the liver, improves insulin sensitivity, and appears to have broad downstream effects on inflammation, cellular aging, and mitochondrial function.

The Longevity Case: TAME and What It Could Mean

The most significant development in metformin's longevity story is the TAME trial, short for Targeting Aging with Metformin. Led by Dr. Nir Barzilai at the Albert Einstein College of Medicine, TAME is the first clinical trial specifically designed to test whether a drug can slow the biological process of aging itself rather than treat individual diseases.

The trial is enrolling 3,000 adults aged 65 to 79 who do not yet have diabetes, following them over six years to assess whether metformin delays the onset of age-related conditions including cardiovascular disease, cancer, cognitive decline, and mortality. The primary endpoint is not treating any single disease. It is slowing the aging process as a whole.

TAME is still ongoing, and we do not yet have results. That is worth saying clearly. But the fact that the FDA granted it the first-ever approval to test a drug for aging as an indication is itself significant. It reflects a serious scientific consensus that the question is worth asking, and that metformin is the right candidate to ask it about first.

The observational data that preceded TAME is what generated that consensus. Multiple large population studies found that diabetic patients on metformin were outliving non-diabetic patients not on any drug, a finding that stopped researchers in their tracks. When the treated population is living longer than the untreated healthy population, you have a signal worth following.

The Surprise: Long COVID

In 2023, a study stopped a lot of people mid-scroll.

The COVID-OUT trial, published in The Lancet Infectious Diseases, was a large randomized controlled trial that originally set out to test whether early outpatient treatment could reduce COVID-19 severity. What it found along the way was unexpected: participants who received metformin had a 41 percent lower rate of long COVID compared to placebo.

Follow-up data presented at IDWeek 2024 continued to support this finding. The proposed mechanisms involve metformin's anti-inflammatory and antiviral properties, its ability to reduce the viral load burden in early infection, and its effects on immune dysregulation, all of which are implicated in the pathophysiology of long COVID.

This is emerging evidence, not settled science. The mechanisms are plausible but not yet fully characterized, and replication in additional trials is needed before this becomes a clinical standard. But for a drug that was already being discussed for its anti-aging potential, finding a signal this strong in the long COVID space expanded the conversation significantly.

Three More Places It Shows Up

So Why Isn't Everyone on It?

Fair question. The honest answer is that medicine moves slowly, and a drug that costs pennies does not have a pharmaceutical company with a marketing budget behind it. Metformin went off patent in 1995. Nobody is running Super Bowl ads for it.

There is also the matter of indication. Metformin is FDA-approved for type 2 diabetes. Prescribing it for longevity or prevention in non-diabetic patients is off-label, which means it requires a clinician who has done the reading, understands the evidence, and is willing to have a nuanced conversation about risk and benefit with their patient.

That conversation is increasingly happening. As the TAME trial progresses and the longevity medicine field matures, metformin is likely to become a more standard part of the preventive medicine conversation. For now, it sits in the space of thoughtful, evidence-informed clinical decision-making for the right patient.

Which is, frankly, where the most interesting medicine usually lives.

This article is for informational purposes and does not constitute medical advice. Metformin is a prescription medication. Whether it is appropriate for you depends on your individual health history, labs, and clinical picture. If you are interested in discussing metformin as part of a preventive health strategy, that conversation starts with a clinician who knows your full story.